Patents by Inventor Tsuyoshi Soneda
Tsuyoshi Soneda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230058950Abstract: An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof, where each symbol in Formula (1) has the same definition as that described in the specification.Type: ApplicationFiled: January 23, 2020Publication date: February 23, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Junya KAWAI, Osamu IWAMOTO, Yuma UMEZAKI, Katsuyoshi NAKAJIMA, Hiroyuki TSURUOKA, Keiji SAITO, Nobuya KURIKAWA, Natsumi NISHIHAMA, Shinji TANAKA, Momoko OGITANI, Tomohiro HONDA, Wataru SAITOH, Tsuyoshi SONEDA, Nobuyuki OHKAWA
-
Publication number: 20220144765Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound represented by the following formula, or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and represent a C1-C6 alkyl group or the like, and Ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.Type: ApplicationFiled: January 26, 2022Publication date: May 12, 2022Applicant: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Yuji Nakamura, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
-
Publication number: 20210206716Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound represented by the following formula, or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and represent a C1-C6 alkyl group or the like, and Ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.Type: ApplicationFiled: March 23, 2021Publication date: July 8, 2021Applicant: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Yuji Nakamura, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
-
Patent number: 10968169Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound represented by the following formula, or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and represent a C1-C6 alkyl group or the like, and Ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.Type: GrantFiled: October 5, 2017Date of Patent: April 6, 2021Assignee: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Yuji Nakamura, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
-
Patent number: 10925848Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. Provided is a pharmaceutical composition containing, as an active ingredient, a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula (I), R1 and R2 are the same or different, and represent a C1-C6 alkyl group, a halogeno C1-C6 alkyl group or a C3-C6 cycloalkyl group; n represents 0, 1 or 2; each X represents a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a halogen atom or the like; and Y represents a hydrogen atom, a C1-C6 alkoxy group, a C3-C6 cycloalkoxy group or a halogeno C1-C6 alkoxy group.Type: GrantFiled: February 20, 2018Date of Patent: February 23, 2021Assignee: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Hiroki Sakai, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
-
Publication number: 20200017439Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound represented by the following formula, or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and represent a C1-C6 alkyl group or the like, and Ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.Type: ApplicationFiled: October 5, 2017Publication date: January 16, 2020Applicant: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Yuji Nakamura, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
-
Publication number: 20190365688Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. Provided is a pharmaceutical composition containing, as an active ingredient, a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula (I), R1 and R2 are the same or different, and represent a C1-C6 alkyl group, a halogeno C1-C6 alkyl group or a C3-C6 cycloalkyl group; n represents 0, 1 or 2; each X represents a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a halogen atom or the like; and Y represents a hydrogen atom, a C1-C6 alkoxy group, a C3-C6 cycloalkoxy group or a halogeno C1-C6 alkoxy group.Type: ApplicationFiled: February 20, 2018Publication date: December 5, 2019Applicant: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Hiroki Sakai, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
-
Patent number: 10399968Abstract: Problem to be Solved There is a need for a new antibiotic having a novel mechanism of action which exhibit strong antibacterial activity not only against sensitive bacteria but also against resistant bacteria thereof, and at the same time possesses excellent solubility an a safety profile amenable to human use. Solution to the Problem As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit possesses excellent solubility and a safety profile for use in humans for the treatment of bacterial infectious diseases.Type: GrantFiled: September 28, 2016Date of Patent: September 3, 2019Assignee: Daiichi Sankyo Company, LimitedInventors: Manoj Kumar Khera, Tarun Mathur, Jitendra A. Sattigeri, Nobuhisa Masuda, Tsuyoshi Soneda, Yoshiko Kagoshima, Toshiyuki Konosu, Tetsuya Suzuki, Makoto Yamaoka, Ryo Itooka
-
Publication number: 20180327399Abstract: Problem to be Solved There is a need for a new antibiotic having a novel mechanism of action which exhibit strong antibacterial activity not only against sensitive bacteria but also against resistant bacteria thereof, and at the same time possesses excellent solubility an a safety profile amenable to human use. Solution to the Problem As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit possesses excellent solubility and a safety profile for use in humans for the treatment of bacterial infectious diseases.Type: ApplicationFiled: September 28, 2016Publication date: November 15, 2018Applicant: Daiichi Sankyo Company, LimitedInventors: Manoj Kumar Khera, Tarun Mathur, Jitendra A. Sattigeri, Nobuhisa Masuda, Tsuyoshi Soneda, Yoshiko Kagoshima, Toshiyuki Konosu, Tetsuya Suzuki, Makoto Yamaoka, Ryo Itooka
-
Patent number: 8975263Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having an excellent glucose lowering effect. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein R1 represents a C1-C3 alkyl group, each substituent R2 may be the same or different and may each represent a C1-C3 alkyl group, R3 represents an optionally substituted pyridyl group or the like, R4 and R5, which are the same or different, each represent a C1-C3 alkyl group, R6 and R7, which are the same or different, each represent a C1-C3 alkyl group, and n represents 0 to 3.Type: GrantFiled: May 30, 2014Date of Patent: March 10, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Shigeo Yamanoi, Katsuji Kagechika, Tsuyoshi Soneda, Yuichi Ochiai, Hidenori Namiki, Fuminao Doi, Madoka Hoshino, Shoko Yoshida
-
Patent number: 8927588Abstract: To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.Type: GrantFiled: September 13, 2013Date of Patent: January 6, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Hiroshi Takeshita, Yoshiko Kagoshima, Yuko Yamamoto, Takafumi Hosokawa, Toshiyuki Konosu, Nobuhisa Masuda, Takuya Uchida, Issei Achiwa, Junichi Kuroyanagi, Tetsunori Fujisawa, Aki Yokomizo, Tetsuji Noguchi
-
Publication number: 20140343052Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having an excellent glucose lowering effect. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein R1 represents a C1-C3 alkyl group, each substituent R2 may be the same or different and may each represent a C1-C3 alkyl group, R3 represents an optionally substituted pyridyl group or the like, R4 and R5, which are the same or different, each represent a C1-C3 alkyl group, R6 and R7, which are the same or different, each represent a C1-C3 alkyl group, and n represents 0 to 3.Type: ApplicationFiled: May 30, 2014Publication date: November 20, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Shigeo YAMANOI, Katsuji KAGECHIKA, Tsuyoshi SONEDA, Yuichi OCHIAI, Hidenori NAMIKI, Fuminao DOI, Madoka HOSHINO, Shoko YOSHIDA
-
Publication number: 20140073622Abstract: To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.Type: ApplicationFiled: September 13, 2013Publication date: March 13, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Hiroshi Takeshita, Yoshiko Kagoshima, Yuko Yamamoto, Takafumi Hosokawa, Toshiyuki Konosu, Nobuhisa Masuda, Takuya Uchida, Issei Achiwa, Junichi Kuroyanagi, Tetsunori Fujisawa, Aki Yokomizo, Tetsuji Noguchi
-
Patent number: 8536197Abstract: An antibiotic compound having a novel mechanism of action, weak cytotoxicity, high solubility in water, effective in inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and having antibacterial activity.Type: GrantFiled: December 26, 2008Date of Patent: September 17, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Tsuyoshi Soneda, Hiroshi Takeshita, Yoshiko Kagoshima, Yuko Yamamoto, Takafumi Hosokawa, Toshiyuki Konosu, Nobuhisa Masuda, Takuya Uchida, Issei Achiwa, Junichi Kuroyanagi, Tetsunori Fujisawa, Aki Yokomizo, Tetsuji Noguchi
-
Publication number: 20100311966Abstract: An antibiotic compound having a novel mechanism of action, weak cytotoxicity, high solubility in water, effective in inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and having antibacterial activity.Type: ApplicationFiled: December 26, 2008Publication date: December 9, 2010Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsuyoshi Soneda, Hiroshi Takeshita, Yoshiko Kagoshima, Yuko Yamamoto, Takafumi Hosokawa, Toshiyuki Konosu, Nobuhisa Masuda, Takuya Uchida, Issei Achiwa, Junichi Kuroyanagi, Tetsunori Fujisawa, Aki Yokomizo, Tetsuji Noguchi